News | April 11, 2022
New very-high-sensitivity rapid antigen test kits hit Australian market
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
New Covid-19 Medriva Rapid Antigen Test kits with very high- sensitivity now available in Australia
The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Although PCM has advanced substantially in recent years, most of the valuable technical information resides with private companies and academic publications across multiple platforms
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
The new unit will be built with INEOS’ latest process technology and aims to substantially improve the sustainability of our supply to our customers and reduce our environmental impact
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
The Blockchain-based solution was awarded the 2021 Bionow Technical Service Award
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Subscribe To Our Newsletter & Stay Updated
